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Abstract: Integration of a reverse transcribed DNA copy of the HIV viral genome into the 
host chromosome is essential for virus replication. This process is catalyzed by the virally 
encoded protein integrase. The catalytic activities, which involve DNA cutting and joining 
steps, have been recapitulated in vitro using recombinant integrase and synthetic DNA 
substrates. Biochemical and biophysical studies of these model reactions have been pivotal 
in advancing our understanding of mechanistic details for how IN interacts with viral and 
target DNAs, and are the focus of the present review.  
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1. Introduction  
HIV-1 integrase (IN) catalyses integration of the reverse transcribed DNA copy of the viral genome 
into a host chromosome (reviewed in [1]), a step which is essential for the retroviral lifecycle. 
Integrase selectively recognizes and synapses the two viral DNA ends to form a catalytically 
competent nucleoprotein complex. Understanding of structural and mechanistic foundations for   
IN-viral DNA interactions have been the subject of intense research as both a fascinating biological 
paradigm and an important therapeutic target for the development of antiretroviral therapies. Practical 
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benefits of these efforts have been manifested by the recent discovery of the strand transfer inhibitors 
(STI) and a successful launch of Raltegravir into the clinic. Strikingly, STIs selectively bind the 
preformed IN-viral DNA complex rather than free protein [2–4], thus exemplifying the significance of 
detailed characterization of the functional nucleoprotein complexes.  
2. DNA Processing and Joining Reactions Catalyzed by HIV-1 IN 
The integration of viral DNA into a host chromosome involves two chemical reactions. In the first 
step, which is called 3’-processing and takes place in the cytoplasm shortly after the viral DNA is 
made, IN hydrolyzes a GT dinucleotide from each 3’ end of the viral DNA. In the second step, IN 
catalyzes concerted integration of the processed viral DNA ends into chromosomal DNA. The sites of 
attack on the two target DNA strands are separated by 5 bp for HIV-1 IN, which leads to DNA strand 
dissociation in the small double-stranded DNA fragment between the attachment sites. The subsequent 
repair of the intermediate species by cellular enzymes completes the integration reaction. 
In infected cells IN functions in the context of a large nucleoprotein complex termed the 
preintegration complex (PIC), where a number of viral and cellular proteins contribute to retroviral 
integration [5–17]. PICs can be extracted from infected cells and used for biochemical assays in vitro 
[18–25]. However, the amounts of these nucleoprotein complexes are not sufficient to perform atomic 
structural or even lower resolution biophysical analyses. Therefore, recombinant IN and model DNA 
substrates have been employed instead to study protein-nucleic acid interactions. Typically, purified 
recombinant protein and short DNA substrates (~21-mer dsDNA mimicking the U5 end of viral DNA) 
are utilized to monitor 3’-processing and strand transfer activities (Figure 1A). These reactions, 
however, do not yield concerted integration products and instead, result in integration of one viral 
DNA end into the target DNA. More recently, assays using a longer donor DNA substrate of several 
hundred basepairs and a second circular target DNA have been devised, which allow effective 
concerted integration of two viral DNA ends [26–31] (see Figure 1B). This improved experimental 
design has furthermore allowed isolation and characterization of critical nucleoprotein intermediates 
that are reminiscent of IN-viral DNA interactions in the PIC in the infected cells [27,28]. 
Along with the biologically relevant 3’-processing and strand transfer activities, purified IN 
exhibits additional activities in vitro. The enzyme can reverse the strand transfer reaction by site 
selectively cleaving the integrated DNA. This reaction is called disintegration [32]. A recent report has 
indicated that the recombinant protein can also catalyze internal cleavage at a palindromic sequence 
mimicking LTR-LTR junction [33,34]. However, there is no evidence as yet that these additional 
catalytic activities observed in vitro can also occur in infected cells.  Viruses 2009, 1                  
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Figure 1. Schematic presentation of HIV-1 IN activity assays in vitro. (A) These reactions 
are typically performed with purified recombinant IN and 21-mer double-stranded DNA 
mimicking the U5 sequence. The enzyme first removes the GT dinucleotide from the   
3’-terminal, and then covalently joins the recessed 3’-end to the target DNA. In these 
reactions the U5 sequence serves as both viral and target DNA. The strand transfer 
products result from integration of only one viral DNA end into the target DNA, while 
pair-wise integration products are not observed. (B) The concerted integration assays and 
critical nucleoprotein intermediates. Selective interaction of IN with viral DNA ends 
results in a highly stable nucleoprotein complex termed the stable synaptic complex (SSC). 
Next, IN in the context of SSC engages with the target DNA to form the strand transfer 
complex (STC), which carries out the concerted integration reaction. These nucleoprotein 
complexes are readily separated by native agarose gel electrophoresis. Deproteinization of 
the STC leads to the formation of the concerted integration product. The asterisks in A and 
B indicate the P
32 labeled 5’-end of viral DNA. 
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3. Structure of HIV-1 Integrase  
IN consists of three distinct structural and functional domains: the N-terminal domain (NTD), the 
catalytic core domain (CCD) and the C-terminal domain (CTD) (Figure 2A). Each domain directly or 
indirectly contributes to IN-DNA interactions. The NTD, which encompasses residues 1–46, is linked 
to the CCD (residues 56–186) through a linker segment of aa 47–55. Another flexible loop comprised 
of residues 187–194 connects the CCD with the CTD (residues 195–288). Results of structural biology 
studies revealed each individual domain as a dimer [35–39]. More recent two-domain crystal structures 
comprised of the CCD and CTD [40] or NTD and CCD [41] likewise unveiled dimeric organizations. 
However, dimer interfaces for individual NTDs [35] and CTDs [38] differ from those observed in the 
two domain fragments [40,41] and it is not clear how these two domains are assembled in full-length 
oligomeric IN. In contrast, the CCD-CCD interactions have remained consistent in various constructs 
[36,37,40–42] suggesting that these protein-protein contacts are likely to be also preserved in the fully 
functional nucleoprotein complex. Structural analyses of the full-length recombinant IN or its 
complexes with model DNA substrates have not been amenable to crystallographic and NMR 
approaches. 
The NTD has a HTH fold that is conserved in all retroviral and retrotansposon integrases [35,41]. It 
contains conserved pairs of histidine (H12, H16) and cysteine (C40 and C43) residues that bind zinc 
[35,43] and contributes to functional oligomerization of IN [44,45]. The mutations of Zn binding 
residues yield monomeric IN and inhibit the 3’-processing and strand transfer reactions [46,47]. 
Furthermore, recent biochemical and structural studies implicated the NTD-CCD interactions in 
functional tetramerization of IN [47,48]. The K14A substitution at the putative NTD-CCD interface 
destabilized IN tetramers and compromised IN catalytic activities [48]. 
The CCD belongs to a superfamily of polynucleotidyl transferases that share an overall fold of 
bacterial RNase H and exhibit a similar catalytic mechanism [36]. HIV-1 IN catalytic site is comprised 
of the invariant triad of acidic residues D64, D116 and E152 that act by binding divalent metal ions 
[49,50]. Mutations of these residues severely compromise IN activities in vitro and in infected cells 
[46,51,52]. Biochemical assays with purified IN revealed that it requires either Mg
2+ or Mn
2+ to carry 
out the reactions with model DNA substrates. Of these, Mg
2+ is considered to be the physiological 
cofactor due to its relative abundance in the cells. Several structural studies have shown a single 
divalent metal bound to the active site of the HIV-1 CCD [37]. However, based on the two-metal 
mechanism for structurally and functionally similar polynucleotidyl transferases [53,54], it has been 
proposed that DNA binding stabilizes the second metal in the active site [55]. IN uses the same 
catalytic site for 3’-processing and strand transfer reactions. Therefore, the CCD is likely to harbor 
both viral and target DNA binding sites. Furthermore, the CCD is also an essential building block for 
formation of the functional multimeric IN. The CCD-CCD interface is fairly large (~1,650 Å
2) and 
mutations destabilizing these interactions adversely affect IN catalytic activities [36,41].  
The C-terminal domain (CTD) is rich in basic amino acids and adopts an SH3-like fold [38]. Other 
proteins with the same fold bind the minor groove of DNA in a nonspecific manner [56–58]. Similarly, 
the CTD is thought to provide a stabilizing platform for DNA substrates. In addition, the CTD has 
been implicated in functional oligomerization of IN. L241A and L242A mutations along the   
C-terminal dimer disrupted IN dimerization and compromised catalytic activities [59].  Viruses 2009, 1                  
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Figure 2. (A) Schematic presentation of the three domain structure of HIV-1 IN. The NTD 
residues (H12, H14, C40 and C43) coordinate Zn and contribute to the functional 
multimerization. It is not entirely clear whether the NTD directly binds viral or target 
DNA. The CCD contains the catalytic DDE motif. This domain interacts with both viral 
and target DNA. A number of residues (Y143, Q148 and K159) selectively interact with 
terminal U5 bases, while S119 has been implicated in direct interactions with the target 
DNA. The CCD is also critical for the functional multimerization. The CTD is highly basic 
and non-specifically interacts with viral DNA. Several CTD residues implicated in viral 
DNA binding are indicated. It remains to be determined whether the CTD could also 
coordinate the target DNA. (B) Sequences of U3 and U5 termini of viral DNA. The base-
pairs that are identical in U3 and U5 sequences are in bold. A majority of IN-viral DNA 
mapping experiments used the U5 sequence and the interacting sites are indicated with 
circles. Note color coordination between the residues in A and respective nucleotide 
positions in B. The catalytic residues in A and the arrow pointing to the specific cleavage 
sites at U3 and U5 termini are in red. The CCD amino acids Y143, Q148 and K159 
(colored green) have been shown to selectively crosslink with the terminal nucleotides 
marked with green circles [60]. The E246C mutant is colored blue and its multiple 
crosslinking sites [61] in viral DNA are depicted by blue circles.  
 
4. Sequence and Structure of Viral DNA 
IN productively binds U5 and U3 termini of viral DNA (Figure 2B). Footprinting of PICs isolated 
from the infected cells revealed the terminal 200–250 base pairs of each viral DNA end as primary 
protein binding sites [19]. In contrast, internal regions of the viral DNA did not exhibit strong protein 
binding. DNase I digestion of the stable synaptic complex assembled with purified IN and long DNA Viruses 2009, 1                  
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substrates implicated much smaller segments of viral DNA. Only terminal 16 and 32 bps were 
protected in the SSCs assembled with the W235H mutant and wild type IN, respectively [27,62]. The 
significantly larger footprint observed in the nucleoprotein complexes isolated from infected cells 
could probably be explained by contributions of other viral and cellular proteins associated with the 
PICs [19].  
Biochemical studies have shown that recombinant IN exhibits comparable affinities with respect to 
specific and non-specific DNA sequences. Oligodeoxynucleotides with random sequences can 
effectively compete with IN-viral DNA interactions and impair the 3’-processing reactions [63–65]. In 
the context of infected cells this inherent property of IN is unlikely to significantly deter the retroviral 
protein from its biological target, the viral DNA ends, as the assembly of the PICs takes place in the 
cytoplasm where competition from non-specific DNA sites are likely to be minimal. Once bound to the 
viral DNA, however, IN forms a very stable nucleoprotein complex [28]. Divalent metal has been 
shown to contribute to assembly and stabilization of HIV-1 IN-viral DNA complex [66–71]. 
Functional assays have shown that IN can distinguish between the viral DNA ends and nonspecific 
substrates. Mutational studies in vitro and ex vivo have indicated the importance of CA/TG 
dinucleotide pair for effective 3’-processing of the viral DNA ends [63]. Additional proximal regions 
of viral DNA have also been implicated in specific recognition of the viral DNA [60]. Mutations at 
positions 11–13 from the U5 terminus substantially compromised 3’-processing activities of 
recombinant IN in the presence of Mg
2+ ions with lesser affects being observed with Mn
2+, suggesting 
a differential effect of divalent metals on sequence specific binding. Another study [72] identified 
positions 17–20 to be important for effective concerted integration in vitro. At the same time these 
experiments indicated that HIV-1 IN could tolerate significant divergence in the viral DNA sequences.  
One important feature contributing to selective recognition of the LTR termini by IN could be the 
DNA end distortion. NMR analysis of a 17 base pair oligonucleotide containing the U5 terminal 
sequence revealed that base stacking and minor groove were significantly disordered at the cleavage 
site [73]. The chemical footprinting of the avian sarcoma virus (ASV) IN complex with cognate DNA, 
moreover, revealed that protein binding further destabilized the terminal three base pairs [74]. 
Significantly, the authors observed a good correlation between DNA end distortion and cleavage 
activities [74]. Introducing mismatch bases at the terminal three positions enhanced base unstacking 
and unpairing, and substantially stimulated the site specific processing activities.  
The alternative experimental strategies to identify the LTR regions important for selective 
recognition involved application of DNA analogs. Probing effects of various DNA backbone, base, 
and groove modifications on IN catalytic activities suggested that IN requires flexibility of the 
phosphodiester backbone at the scissile bond [75]. The other study examined 2’-modified nucleosides 
and 1,3-propanediol insertions in various positions of the U5 sequence [76]. Akin to the mutagenesis 
experiments [60] divalent metal dependent effects were observed upon altering certain regions of the 
DNA [76]. Nucleoside modifications at positions 3, 5 and 6 significantly diminished Mg
2+ dependent 
activities, while Mn
2+ dependent reactions were less affected. In contrast, Mg
2+ and Mn
2+ dependent 
activities were equally impaired when the modifications were introduced at positions 7–9 [76]. Taken 
together, the biochemical approaches enabled the delineation of several important features of viral 
DNA essential for formation of the functional nucleoprotein complexes. Nevertheless, the detailed Viruses 2009, 1                  
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mechanism for selective recognition remains elusive. Ideally, atomic structures of IN complexes with 
specific and non-specific DNAs would be necessary to fully address this question.  
5. Mapping HIV-1 IN-Viral DNA Interactions 
IN functions as a multimer. Mutagenesis experiments have shown that two inactive mutants of IN 
with substitutions in different domains of the protein can be combined to regain the catalytic function 
[77–79]. These results have indicated that different monomers within the IN multimer provide 
complementary rather than symmetrical contacts to DNA [77–79].  
At the sub- to low-micromolar concentrations of IN normally used in the in vitro activity assays, the 
protein exists as a mixture of monomers, dimers and tetramers in the absence of DNA [64,80–82]. 
Interactions between individual subunits are highly dynamic in the unliganded IN [48], but are 
stabilized by DNA binding [27]. Time resolved fluorescence anisotropy measurements indicated that 
individual IN subunits bind viral DNA in a cooperative manner with a stoichiomery of two IN 
monomers bound to each viral DNA end [34,83]. Small angle X-ray scattering experiments have also 
indicated that monomeric IN could assemble onto a short specific DNA as dimers and effectively 
catalyze 3’-processing reactions [84]. These studies have suggested that a dimeric IN could suffice to 
process one viral DNA end [85,86].  
A number of studies have suggested that a tetramer of IN synapses the two viral DNA ends into the 
fully functional nucleoprotein complex. Crosslinking experiments have revealed IN tetramers as a 
dominant species in the nuclear extracts of infected cells [14]. Consistently, the stable synaptic 
complexes assembled in vitro contained a tetrameric form of IN [27]. Efforts to more directly visualize 
the size of the nucleoprotein complexes included atomic force microscopic analysis of ASV IN in its 
free form and in the complex with cognate short DNA, which also demonstrated substrate-induced 
assembly of the IN tetramer [87]. Similar results were obtained by electron microscopy and singe-
particle image reconstruction of HIV-1 IN complex with a model DNA junction mimicking the pair-
wise integration structure [88]. Other studies [62,89], however, proposed that a higher order oligomer 
(for example, octamer) of IN could be formed during the concerted integration. We will return to 
discussion of IN oligomeric states later in the context of IN interactions with its principal cellular 
cofactor lens epithelium derived growth factor (LEDGF/p75).  
To identify IN amino acids directly interacting with DNA substrates photo and chemical cross-
linking studies have been conducted [60,89–93]. These experiments revealed several key contact 
points. For example, the CCD residues (K159, Q148 and Y143) have been shown to specifically tether 
with the nucleotide analogs incorporated at the terminal portion of the viral DNA ends [60,90]. K159 
is part of the helix containing the catalytic E152 and could directly interact with viral DNA. Y143 and 
Q148 are situated in the flexible loop and could contribute to accurate positioning of viral and target 
DNA substrates. Consistent with this, Pommier and co-workers have found that the STI   
1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone effectively interrupted the disulfide 
cross-linking between Q148C and the C2 of viral DNA, suggesting the importance of these 
nucleoprotein contacts for the strand transfer step [92].  
IN-viral DNA crosslinking experiments have also implicated a number of the CTD residues in 
interactions with distal segments of the LTR [60,89,93,94]. The reactive bases introduced in the region Viruses 2009, 1                  
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centered at 6–7 base-pairs from the U5 terminal were found to effectively tether with the CTD amino 
acids. For example, Gao et al. observed a strong crosslink between the E246C mutant and position A7 
[94]. However, analysis of additional DNA positions (G2, G5, A7, G16 and G19) conducted by our 
group revealed comparable reactivity of E246C with all the substrates examined [61]. The latter results 
are consistent with the non-specific mode of the CTD-DNA interactions and indicate that the exact 
locations of the CTD in the functional nucleoprotein complex could not be reliably determined from 
these experiments. Indeed, even though the U5 sequence has been used in these experiments, IN could 
bind with equal affinity to specific and non-specific ends of the 21-mer double stranded DNA thus 
differently positioning the CTD on the DNA. It should also be noted that majority of the CTD contacts 
implicated in DNA binding are lysines and arginines [61], which could potentially engage in charge-
charge interactions with the phosphate backbone of viral DNA.  
Sequence alignments between HIV and other retroviral INs have also been exploited for 
identification of IN amino acids contributing to viral DNA recognition. Leis and coworkers introduced 
several ASV IN residues at analogous positions in HIV-1 IN and monitored whether these 
substitutions altered their preferences for LTR sequences [95,96]. HIV-1 IN residues that changed 
specificity included V72, S153, K160, I161, G163, V165, H171 and L172 suggesting that these amino 
acids could directly or indirectly contribute to viral DNA recognition. In separate studies highly 
conserved HIV-1 IN residues were targeted by site directed mutagenesis to evaluate their roles for 
virus replication [97,98]. The authors grouped the mutations that solely affected the integration step in 
class I, while the substitutions that exhibited additional assembly and/or reverse transcription defects 
were placed in class II. Overall, these ex vivo experiments [97,98] have been instrumental for 
dissecting the functionally essential residues and validating the biological importance of a number of 
amino acids identified from in vitro analysis of model IN-viral DNA complexes.  
Several lines of evidence have emerged that IN undergoes significant conformational change upon 
DNA binding. Our mass spectrometry (MS) based footprinting experiments have uncovered DNA 
induced structural rearrangement involving the flexible loop between the CCD and CTD [61]. 
Bushman and coworkers have detected differential cross-linking of CTD residues with blunt ended and 
processed DNA substrates, suggesting protein structural changes upon cleavage of the viral DNA 
terminus [94]. Asante-Appiah and Skalka have revealed a metal dependent-conformational 
rearrangements, which affected the recognition of the CCD and CTD, but not the NTD, by domain 
selective antibodies [99]. Roth and co-workers have found that the functional IN tolerated the insertion 
of a 19 amino acid sequence at the helix connecting the CCD and CTD [100]. These observations 
collectively point to the importance of the linker loop of aa 187–194 (Figure 2A) for providing much 
needed flexibility to the CCD and the CTD to productively assemble onto viral DNA. 
6. HIV-1 IN Interactions with the Target DNA 
In common with other retroviruses HIV-1 IN exhibits a weak primary sequence preference for 
integration sites [101–107]. While in cells different retroviruses display distinguishable integration site 
preferences, the target DNA sequence is probably a minor contributor to this. In the case of HIV-1 the 
interactions of the retroviral enzyme with chromatin are strongly mediated by the cellular transcription Viruses 2009, 1                  
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coactivator LEDGF/p75 and active genes are favored for integration (see [108, 109] for recent reviews 
and the following chapter).  
In vitro experiments have indicated that a wide variety of DNA sequences could serve as targets for 
the stand transfer reactions [101–104]. At the same time a number of studies noted preferential 
integration in distorted DNA sites [110,111]. For example, in vitro ASV and HIV INs primarily 
targeted sites adjacent to stem loop structures in a plasmid DNA cruciform [112]. The importance of 
the target DNA distortion for effective integration has also been noted in the context of chromatinized 
templates [110–114]. DNA assembled into nucleosomes was more favorable for integration than naked 
DNA with the most bent regions of DNA on the nucleosomes being preferentially targeted [110–114].  
To identify IN residues interacting with the target DNA, Katzman and co-workers used an elegant 
approach in which they compared sequence variations in patient-derived HIV-1 integrases with 
alterations in the preferred integration sites in the target DNA and identified a small number of amino 
acids substitutions [115]. These substitutions were then examined for their interactions with the target 
DNA in vitro. These experiments have clearly delineated the importance of HIV-1 IN residue S119 for 
the target site selection, while the substitutions at this position did not affect IN interactions with viral 
DNA [115]. More recent efforts from the same group have extended the target DNA binding platform 
to include 5 additional CCD amino acids [116].  
Earlier crosslinking studies have suggested that the NTD and the CCD could also interact with the 
target DNA [89,93]. However, these experiments were performed with the dumbbell DNA, which is a 
substrate for disintegration rather than for 3’-processing or stand transfer reaction. Furthermore, 
detailed mutagenesis studies of the NTD and the CTD residues [46,48,98,117–119] failed to identify 
phenotypes resembling to those observed with S119 substitutions [115]. Mutations of functionally 
significant residues in the NTD and CTD equally impaired 3’-processing (which does not involve 
interactions with the target DNA) and stand transfer activities. Therefore, it remains obscure whether 
the NTD and the CCD could directly contribute to target DNA binding.  
7. Concerted Integration Intermediates 
The majority of biochemical and biophysical studies reviewed above have been conducted using 
recombinant IN and short DNA substrates and revealed important details for IN-DNA interactions. 
However, these reaction conditions yield integration of only one viral DNA end into the target DNA 
(termed as half-site integration), rather than concerted integration of a pair of viral DNA ends (termed 
as full-site integration) as occurs in vivo. More recently, modifications of reaction conditions allowed 
effective full-site integration of two viral DNA ends [26–31]. The most notable change in the assay has 
been the replacement of short DNAs with a longer donor DNA substrate (~1 kbps) and a second 
circular target DNA (compare Figures 1 A and B). It is unclear why longer donor DNA substrates are 
favored for the pair-wise integration, given that IN selectively binds only a small terminal region of 
viral DNA. It has also been noted that preprocessed DNAs preferentially yield half-site reaction 
products, while the blunt-ended DNA substrates are more efficient for full-site integration [26].  
The optimized reaction conditions allowed Li et al. to isolate and characterize critical nucleoprotein 
intermediates involved in the pair-wise integration [27,28]. Using the azido-containing aryl β-diketo 
acid inhibitor the authors effectively trapped the first important reaction intermediate, the stable Viruses 2009, 1                  
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synaptic complex formed between a tetramer of IN and two viral DNA ends. Particularly noteworthy is 
the observation that the SSC is as stable as the integrase complex with viral DNA assembled in the 
context of the PIC [27,28]. The SSC effectively resists treatments with the buffers containing high 
ionic strength or detergents. In contrast, stable nucleoprotein complexes are not formed upon IN 
interactions with a single viral DNA end in reactions that lead to half-site integration or with long 
DNAs that lack the LTR sequence [27,28]. 
The 3’-processing reactions take place within the SSC. IN remains stably associated with the pair of 
viral DNA ends and engages target DNA to form a second stable complex termed the strand transfer 
complex (STC) [27,28]. This complex carries out concerted integration of the pair of viral DNA ends 
into target DNA. Li et al. have monitored the reaction time course with two-dimensional gel 
electrophoresis and found that two DNA strand transfer steps occur sequentially and exhibit slow 
kinetics [27]. At early reaction time points the authors detected the intermediate species, which 
contained one viral DNA covalently integrated into the target DNA, while the other viral DNA was 
non-covalently held within the STC. At the later time points, however, essentially all the STC 
contained both viral DNA ends integrated, suggesting that once the correct nucleoprotein complex is 
assembled, the concerted integration is highly efficient [27].  
8. LEDGF/p75 Strongly Modulates HIV-1 IN-DNA Interactions 
LEDGF/p75 is a principal binding partner for HIV-1 and other lentiviral INs and markedly 
enhances the integration process in the infected cells (see [109] for recent review). The cellular protein 
functions as a bifunctional tether: its C-terminal part contains integrase binding domain (IBD) that 
directly engages lentiviral IN, while the N-terminal part tethers the PICs to the chromatin. In vitro 
experiments carried out with purified proteins and model DNA substrates indicated that LEDGF/p75 
strongly modulates strand transfer activities [30,47,48,120,121]. In the reactions with short donor 
DNA substrates and circular target plasmid, LEDGF/p75 potently enhanced both half-site and 
concerted integration reactions [47,120,122]. However, in the assays with long donor DNA substrates, 
the cellular cofactor almost exclusively stimulated integration of only one viral DNA end [30,48]. The 
reasons for different outcomes with short and long donor DNA substrates are not understood.  
Interestingly, order-of-addition experiments performed with long donor DNA indicated that   
sub-stoichiometric amounts of LEDGF/p75 added to the preformed IN-viral DNA complex modestly 
stimulated concerted integration [30]. However, preincubation of LEDGF/p75 with IN and subsequent 
addition of viral DNA to the reaction selectively impaired concerted integration, whereas the half-site 
strand transfer was markedly elevated [30]. While the structural basis for these observations has been 
obscure, initial clues have emerged from recent MS footprinting and x-ray crystallographic studies of 
IN-LEDGF/p75 interactions [47,48].  
Our group has shown that direct binding of LEDGF/p75 or LEDGF IBD strongly stabilizes highly 
dynamic interactions of IN subunits and promotes IN tetramerization [48]. Furthermore, MS 
footprinting experiments identified intra- and inter-protein-protein interactions and enabled detailed 
modeling of the complex (Figure 3A) [48]. The model has suggested that in the preformed   
IN-LEDGF/p75 complex a pair of active sites of IN are separated about ~29 Å, which would enable 
the retroviral enzyme to effectively catalyze 3’-processing and strand transfer reactions. However, the Viruses 2009, 1                  
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concerted integration would not be efficient as this distance is larger than the ~15 Å or 5 bps 
separation expected between two insertion sites in the target DNA (Figure 3A). This model is 
consistent not only with in vitro functional studies [30,48,121] but also with the observations in 
infected cells [5,123]. For example, overexpression of the IBD effectively impaired HIV-1 replication 
in target cells [5,123]. Of note, the IBD was significantly more effective at suppressing HIV-1 
replication in LEDGF/p75 deficient cells (555-fold) compared with cells containing normal 
LEDGF/p75 levels (~30-fold) [5]. A potential competition between the IBD and endogenous 
LEDGF/p75 cannot fully explain these observations. Instead, in vitro functional assays and MS-
footprinting experiments suggest that the IBD binding to IN prior to IN-viral DNA complex formation 
could stabilize a tetrameric form of IN, which is not fully functional [48]. Collectively, these findings 
suggest that HIV-1 IN tetramers formed in the IN-viral DNA and IN-LEDGF/p75 complex may not be 
identical and that the productive integration would require the following sequence of events. Highly 
dynamic HIV-1 IN subunits first assemble onto two viral DNA ends to form the stable synaptic 
complex, where two catalytic sites position themselves for pair-wise integration. This IN tetramer-viral 
DNA complex then binds LEDGF/p75, with the cellular protein directing the PICs to the active genes 
without significantly affecting the prearranged IN-viral DNA conformations.  
Studies with other lentiviral INs have also indicated differential modulation of their function and 
structure by LEDGF/p75. For example, the cellular cofactor almost exclusively stimulated concerted 
integration catalyzed by equine infectious anemia virus IN, while the addition of LEDGF/p75 to 
bovine immunodeficiency virus IN equally enhanced half- and full-site integration products [124]. 
Recently a co-crystal structure of maedi-visna virus (MVV) IN in the complex with the IBD has been 
reported, which has revealed four distinct tetrameric forms of this lentiviral IN in the complex with 
LEDGF/p75 [47]. Of these, in three tetramers the spacing between a pair of DDE motifs was 
significantly greater (~ 27 Å) than that required for concerted integration. These findings agree very 
well with our model for the HIV-1 IN-LEDGF/p75 interactions [48] (also see Figure 3A), and 
reinforce the notion that relative positioning of the two active sites could indeed be one of the main 
reasons for differential modulation of strand transfer activities by LEDGF/p75.  
Of note, one of MVV IN tetramers observed in the crystallographic studies contained a pair of 
active sites optimally situated to carry out effective concerted integration reactions [47]. Significant 
variations in relative positioning and orientations between the two dimers allowed a pair of DDE 
motifs from opposing CCDs to approach 15 Å separation [47]. The results with MVV IN have been 
exploited to build a molecular model for the HIV-1 counterpart [47] (also see Figure 3B). Comparison 
of the two models (Figures 3A and B) reveals “open” and “closed” conformations for IN tetramers. It 
is now of significant interest to clarify whether there is a correlation between the relative abundance of 
these two distinct tetrameric forms of IN in the reaction mixture and relative yield of half- and full-site 
integration products. Studies to test these potential structure-function relationships are currently 
underway in our group and very likely also in other laboratories.  Viruses 2009, 1                  
 
 
724
Figure 3. Molecular models for two distinct forms of HIV-1 IN tetramers. (A) An “open” 
conformation of tetrameric IN. This model is based on the HIV-1 IN two domain (NTD-
CCD) structure [41] and our MS footprinting results [48] indicating that such a 
conformation is stabilized by LEDGF/p75 in the absence of viral DNA. This “open” 
conformation of tetrameric IN could catalyze 3’-processing and half-site integration 
reactions, however an incorrect spacing (~29 Å) between the two active sites would 
hamper the concerted integration. (B) A “closed” conformation of HIV-1 IN tetramer. This 
model was built by Hare et al. using one of the crystal forms of the MVV IN structure [47], 
where the catalytic sites are positioned optimally for concerted integration. It has been 
proposed that this structure could be stabilized by two viral DNAs [47]. However, viral 
DNAs have not been included in the model. Instead, the relative positioning of two 
catalytic sites with respect to the target DNA is shown to demonstrate the 5 bps separation 
consistent with a pair-wise integration. Red arrows point to the target scissile bonds. 
Individual subunits are colored cyan, green, yellow and orange. Side chains of catalytic 
residues in green and yellow subunits are depicted in red. For clarity only NTD-CCD 
fragments are depicted, while the CTDs, which are also present in these models [47,48], 
are not shown.  
 
 
9. Molecular Modeling of the Functional Nucleoprotein Complexes  
Crystallographic determination of the two-domain structures prompted molecular modeling 
research [41,61,89,94,95,125–129]. The two crystal structures [40,41] can be superimposed through 
the common CCD to generate a plausible model for the full length protein. Biochemical and 
biophysical results reviewed above have further aided in positioning viral DNA in the multimeric IN. 
Additional clues for IN-DNA interactions have been provided from the crystal structure of prokaryotic 
transposase 5 (Tn5) in complex with cognate DNA (reviewed in [130]). Tn5 and HIV-1 IN share the 
structurally and functionally similar CCDs. Moreover, the crystal structure implicates individual Tn5 
subunits in establishing complementary contacts with cognate DNA [130], which parallels well with 
the asymmetric mode of viral DNA binding to HIV-1 IN protomers [77–79].  
A majority of the models generated up to date implicate the IN tetramer in interactions with two 
viral DNA ends [41,61,94,95,126–129]. Such a stoichiometry for protein-DNA interactions is Viruses 2009, 1                  
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supported by a number of experimental results [14,27,87,88]. Despite this principal agreement the  
IN-DNA models obtained by different groups vary significantly in positioning individual protein 
subunits and domains as well as DNA binding channels in the nucleoprotein complex, indicating that 
the available experimental data comprises an insufficient number of constraints for formulating a 
common outcome [41,61,89,94,95,125–129]. Indeed, while there is a good consensus that different 
monomers provide complementary contacts to viral DNA, it is not clear whether these interactions are 
enabled by individual subunits within a dimeric IN, or two subunits each from separate dimer 
contribute to viral DNA binding. Therefore, some modeling studies [61,125,126] employed a strategy 
where one viral DNA was coordinated to IN dimer and then two IN dimer-viral DNA complexes were 
assembled together to compose the SSC. Alternative approaches [41,127,128] have considered 
utilizing IN tetramer as a minimal viral DNA binding platform, where two dimers are stabilized by two 
viral DNA ends. 
The absolute requirement for every modeling analysis has been to position DDE motifs over the 
respective scissile bond [41,61,89,94,95,125–129]. The crosslinking and mutagenesis data implicating 
immediate vicinity of the catalytic site in interactions with terminal bases of viral DNA [60,90] are 
also normally considered in these in silico experiments. Furthermore, the available models implicate 
the CCD in direct interactions with the target DNA, which is consistent with the experimental findings 
indicating the role of S119 in the target site selection [115,116].  
The published models also agree that the CTD interacts with viral DNA. However, exact 
positioning of this domain with respect to viral DNA sequence varies significantly. This is not 
surprising given a non-specific nature of the CTD-DNA interactions observed in crosslinking studies 
[61]. The available models disagree regarding the role of the CTD in coordinating the target DNA. As 
discussed above, while earlier crosslinking experiments suggested potential binding of the CTD with 
the target DNA in the context of the dumbbell DNA, these interactions could not be confirmed by 
detailed mutational analysis. Therefore, the exact role of the CTD in target DNA binding remains 
uncertain.  
The main inconsistency between different models is in asserting the role of the NTD. In some 
models the NTD is implicated in direct interactions with viral DNA [61,125], while other studies limit 
its contributions to protein-protein contacts [41,126–128]. Our MS-based footprinting analysis of the 
IN-DNA complex has revealed DNA dependent shielding of the surface accessibility of N-terminal 
K14 [61]. However, protections in the nucleoprotein complex could arise from direct protein-DNA or 
DNA induced protein-protein interactions. Further site directed analysis from our group [48] clarified 
the importance of K14 for dimer-dimer interactions, which in turn is essential for formation of the 
catalytically competent IN tetramer. Our findings [48] have been fully corroborated by more recent 
crystallographic analysis of the MVV IN-IBD complex [47], which show that the tetrameric structure 
is stabilized by intermolecular interactions between the NTD of one dimer and the CCD of another 
dimer. Yet, what configurations the NTDs adopt in the context of the full length protein or its complex 
with viral and target DNAs remains enigmatic. 
The recent two domain structure of MVV integrase tetramer [47], where two active sites are 
optimally positioned for concerted integration provides a new useful building block for modeling 
experiments. In fact, Hare et al. have been able to superimpose partial HIV-1 integrase structures onto 
their MVV structure to generate a model of the full-length tetramer devoid of significant steric clashes Viruses 2009, 1                  
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[47]. The authors have suggested that such a tetramer could be stabilized by the bound DNA, but at the 
same time, they have acknowledged that the protein could undergo significant conformational change 
upon viral DNA binding. Thus, the efforts to generate a plausible model for the synaptic complex 
continue.  
10. Remaining Questions and Outlook 
A wealth of biochemical and biophysical data has been generated over the past two decades and 
provided insights into HIV-1 IN-DNA recognition mechanisms. Yet, atomic details of the protein-
nucleic acid interactions are missing. Instead, the two domain structures of HIV-1 IN have been 
determined and formed a platform for molecular modeling research. However, a complex nature of the 
multi subunit arrangements in the functional complex and the asymmetric mode of viral DNA binding 
have presented a real challenge to generate a consensus model for the IN-viral DNA complex. Where 
do we go from here? Below we outline a few priority areas as a part of a wider roadmap toward 
detailed understanding of structural and mechanistic details of HIV-1 integration.  
Crystallographic efforts to determine the IN-viral DNA structure are ongoing. Recently, high 
concentrations of purified IN-DNA complexes were obtained as required for structural determination 
[131]. For this, Alian et al. used soluble mutant IN and disulfide-mediated crosslinking to stabilize the 
nucleoprotein complex [131]. Significantly, this complex was functionally competent and coordinated 
STI. Further adjustments may still be required, though, to obtain the complex amenable to atomic 
analysis. Alternative strategies involve using other retroviral enzymes. For example, recombinant 
prototype foamy virus IN from the Spumavirus genus is highly soluble and robustly catalyzes the 
concerted integration reactions with 16-bps substrates [132], thus presenting an intriguing model for 
detailed structural analysis.  
Recent reports have defined a powerful in vitro model system for assembly of the SSC that closely 
mimic IN-viral DNA interactions in PICs [26–31]. A logical continuation of these studies is to scale up 
the SSC preparations for their subsequent characterization with various biophysical approaches. For 
example, we are currently analyzing the SSCs with the MS-based footprinting method. Equally, the 
applications of other experimental tools previously utilized in studies with IN-short DNA complexes 
can now be extended to probing the concerted integration intermediates. These experiments could shed 
light on organization of individual protein subunits within the fully functional nucleoprotein complex.  
While there is a general consensus that the principal function of LEDGF/p75 is to tether PICs to the 
chromatin, many important structural and mechanistic details regarding how LEDGF/p75 modulates 
IN interactions with viral DNA or navigates the SSC through the chromatinized DNA remain to be 
elucidated. Moreover, we still do not understand why the length of viral DNA so dramatically affects 
the pair-wise integration. Particularly puzzling are the observations that LEDGF/p75 can stimulate 
both half- and full-site integrations with short DNA, while the cellular cofactor selectively impairs the 
concerted integration with long donor DNA substrates. The efforts to further optimize in vitro reaction 
conditions will continue to approach conditions and the efficacy of concerted intergration observed in 
infected cells. Toward this end a recent study has established in vitro conditions, where reconstituted 
polynucleosomes serve as target acceptor templates for physiologically relevant analysis of the Viruses 2009, 1                  
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integration process [133]. Further in vitro and ex vivo experiments are warranted to elucidate important 
details of how LEDGF/p75 promotes integrase-chromatin interactions. 
Recent biochemical and structural studies have indicated the highly flexible nature of IN subunit-
subunit interactions, and that assembly of the fully functional nucleoprotein complex requires very 
accurate interplay between interacting subunits [47,48]. It is intriguing to exploit this complex multi 
subunit organization as a novel therapeutic target. A broad skepticism for developing small molecule 
inhibitors for protein-protein interactions can be met with the alternative hypothesis that the potential 
inhibitors could stabilize inactive conformation of multimeric IN rather than compete with subunit-
subunit interactions. A rationale for this is provided by the observations that IBD stabilizes a 
tetrameric form of IN, which effectively catalyzes 3’-processing and half-site integration, but is 
selectively impaired for concerted integration [48]. As further proof-of-principal we have recently 
shown that a small molecule inhibitor can stabilize a functionally compromised multimeric form of 
HIV-1 IN [134]. Further research in this direction may well lead to the development of new allosteric 
inhibitors of IN that could complement Raltegravir and other retroviral compounds in treating aids 
patients. 
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